دورية أكاديمية
Cross-Reactivity of Antibodies to Rituximab with Other Therapeutic Anti-CD20 Antibodies.
| العنوان: | Cross-Reactivity of Antibodies to Rituximab with Other Therapeutic Anti-CD20 Antibodies. |
|---|---|
| المؤلفون: | Rispens T; Department of Immunopathology, Sanquin Research and Landsteiner Laboratory, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, the Netherlands.; Amsterdam Institute for Infection and Immunity, Amsterdam, the Netherlands., Kuijpers TW; Amsterdam Institute for Infection and Immunity, Amsterdam, the Netherlands.; Department of Pediatric Immunology, Rheumatology and Infectious Disease, Amsterdam UMC, location AMC, University of Amsterdam, Amsterdam, the Netherlands., Killestein J; Amsterdam UMC location Vrije Universiteit Amsterdam, Neurology, Amsterdam, the Netherlands., van Kempen ZLE; Amsterdam UMC location Vrije Universiteit Amsterdam, Neurology, Amsterdam, the Netherlands., Bloem K; Antibodies and Immunogenicity, Sanquin Diagnostic Services, Amsterdam, the Netherlands. |
| المصدر: | Journal of immunology (Baltimore, Md. : 1950) [J Immunol] 2024 Feb 15; Vol. 212 (4), pp. 529-533. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: American Association of Immunologists Country of Publication: United States NLM ID: 2985117R Publication Model: Print Cited Medium: Internet ISSN: 1550-6606 (Electronic) Linking ISSN: 00221767 NLM ISO Abbreviation: J Immunol Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: Bethesda, MD : American Association of Immunologists Original Publication: Baltimore : Williams & Wilkins, c1950- |
| مواضيع طبية MeSH: | Antigens, CD20*/metabolism , Antibodies, Monoclonal*, Humans ; Rituximab/therapeutic use |
| مستخلص: | One reason for a lack of response to rituximab as well as infusion-related anaphylactic adverse events is the development of antidrug Abs to rituximab. Besides rituximab, a number of other therapeutic Abs targeting CD20 are nowadays available as alternatives. In this study, we investigated the potential cross-reactivity of (human) anti-rituximab Abs to three other anti-CD20 mAbs: ofatumumab, obinutuzumab, and ocrelizumab. In 25 cases of anti-rituximab Abs, cross-reactivity was examined using both direct binding assays and inhibition immunoassays. Although no cross-reactivity was observed to ofatumumab or obinutuzumab, 8 of 25 samples also showed reactivity toward ocrelizumab in at least one of the two assays. Furthermore, in three cases of anti-ocrelizumab Abs, cross-reactivity to rituximab was observed in an inhibition immunoassay, albeit not in a direct binding assay. Our results suggest that obinutuzumab or ofatumumab are safe anti-CD20 alternatives in case of the presence of anti-rituximab Abs. It is advisable to proceed cautiously if switching from rituximab to ocrelizumab (or vice versa) is considered in case these alternatives may not be available. (Copyright © 2024 by The American Association of Immunologists, Inc.) |
| المشرفين على المادة: | 4F4X42SYQ6 (Rituximab) 0 (Antigens, CD20) 0 (Antibodies, Monoclonal) |
| تواريخ الأحداث: | Date Created: 20231227 Date Completed: 20240207 Latest Revision: 20240207 |
| رمز التحديث: | 20240207 |
| DOI: | 10.4049/jimmunol.2300647 |
| PMID: | 38149924 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 1550-6606 |
|---|---|
| DOI: | 10.4049/jimmunol.2300647 |